Skip to main content
UCL Logo Navigate back to homepage

Main navigation

  • Home
  • Study

    Study

    • Study at UCL
    • Prospective students
    • Current students
    • Accommodation
    • Careers
    • Doctoral School
    • Immigration and visas
    • Student finances
    • Support and wellbeing
  • Research

    Research

    • Research at UCL
    • Engage with us
    • Explore our Research
    • Initiatives and networks
    • Research news
  • Engage

    Engage

    • Engage with UCL
    • Alumni
    • Business partnerships and collaboration
    • Global engagement
    • News and Media relations
    • Public Policy
    • Schools and priority groups
    • Give to UCL
  • About

    About

    • About UCL
    • Who we are
    • Faculties
    • Governance
    • President and Provost
    • Strategy
    • UCL's Bicentenary

Panos's story

After three unsuccessful courses of chemotherapy, Panos underwent CAR T-cell therapy, which proved to be a 'miraculous treatment' for him.

Panos, 61

Breadcrumb trail

  • Faculty of Medical Sciences

Breadcrumb trail

  • Faculty of Medical Sciences
  • Panos's story

Panos, 61, had been diagnosed with lymphoma and had undergone three unsuccessful courses of chemotherapy. Following this, he had a stem cell transplant, which was intended to grant him up to five years without cancer. It was hoped that, within this timeframe, new treatments might become available which would be better able to target his condition.

However, within five months, he received the devastating news that his lymphoma had returned for the fourth time.
 
As Panos puts it, he was not sure that he would reach his 60th birthday. 

“We were running out of options. I was ready to die, essentially. I accepted the news that there was nothing else that could be done, and I was ready for it, I was prepared for it.”

The physical toll was immense. Just to prevent his lymphoma from getting worse, Panos was having frequent blood transfusions and hospital treatment. During this, he had an infection, which left him hospitalised for a week.

It was then that Panos’s consultant at UCLH put his name forward for a CAR T-cell therapy trial. An anxious wait followed, but three days after his referral, he received a phone call inviting him for preliminary tests.
 
For Panos, this was a lifeline. “It was very emotional when I received that phone call, both for me and for my family, because that was another chance. It was the best news I’d had over the last four or five years.”

After years of unsuccessful treatment, Panos began CAR T-cell therapy in October 2020 as part of a clinical trial in which he was the second person to enrol.
 
“It was nothing like what I expected it to be. I was only in hospital for two weeks, and I only had two bad days - I was on the verge of catching pneumonia, but my doctors quickly spotted it and treated it.
 
“Most of the time I spent outside chatting with nurses and doctors and visiting the Macmillan Cancer Centre. I wasn’t unwell; in fact, I was the best I’d felt for five years. And I was regularly monitored.”
 
When the all-clear came, it was great news: “For me, it was a miraculous treatment, and it still is, I’m pleased to say.” He is immensely grateful to the team at UCLH who looked after him: “I do get emotional every time I express my gratitude to them - I owe them my life, essentially, and I thank them for it, and I will be grateful for as long as I live.”
 
In August 2022, for the first time since his initial diagnosis, Panos was able to take a long-awaited family trip to Greece, spending time driving back across Europe with his son. It was an emotional journey following his years of treatment. 

“I thought that now the coronavirus has weakened, I could go for that much-deserved family holiday. And I’m so happy to have done that and to be here talking to you.”

Support us

If you are interested in supporting the work we do, you can donate to support cancer research at UCL, or contact advancement@ucl.ac.uk to discuss making a donation or leaving a gift for cancer research in your will.

Donate 

Highlights in Medical Sciences

Drug to treat aggressive leukaemia approved for use in adults
Fluorescence microscopy image of immune cells, showing blue-stained nuclei surrounded by green cell membranes with red marker signals indicating specific proteins or activity within the cells.

Research

Drug to treat aggressive leukaemia approved for use in adults

Adult patients with aggressive leukaemia will soon be able to receive a breakthrough immunotherapy, developed by UCL researchers, on the NHS after approval by NICE.

Millions could benefit from faster prostate cancer scan
healthy prostate scan

Research

Millions could benefit from faster prostate cancer scan

Results of the PRIME trial involving UCL Medical Sciences researchers have found that a quicker, cheaper MRI scan was just as accurate at diagnosing prostate cancer as the current 30-40 minute scan.

10 September 2025

UCL Cancer Institute awarded Athena SWAN Gold
Athena Swan Gold Award

Award

UCL Cancer Institute awarded Athena SWAN Gold

The UCL Cancer Institute has been awarded Athena SWAN Gold in recognition of its sustained commitment to advancing gender equality in higher education and research.

20 May 2025

UCL footer

Visit

  • Bloomsbury Theatre and Studio
  • Library, Museums and Collections
  • UCL Maps
  • UCL Shop
  • Contact UCL

Students

  • Accommodation
  • Current Students
  • Moodle
  • Students' Union

Staff

  • Inside UCL
  • Staff Intranet
  • Work at UCL
  • Human Resources
UCL Logo

University College London, Gower Street, London, WC1E 6BT

Tel: +44 (0) 20 7679 2000

UCL social media menu

  • Link to Instagram
  • Link to LinkedIn
  • Link to Youtube
  • Link to TikTok
  • Link to Facebook
  • Link to Bluesky
  • Link to Threads
  • Link to Soundcloud
Here, it can happen.
Back to top

Essential

  • Disclaimer
  • Freedom of Information
  • Accessibility
  • Cookies
  • Privacy
  • Slavery statement
  • Log in

© 2026 UCL